Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Cancer Genetics today announced that it has signed definitive agreements to sell 2,750,000 shares of common stock to institutional investors for roughly $5.5 million in gross proceeds.

For each share purchased, the investors will also receive an unregistered warrant to buy one-half of a share of common stock at an exercise price of $2.25 a share, CGI said. The warrants are exercisable six months from the date of issuance and expire five years after their initial exercise date.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.